S81428 |
AMI-1 |
MedMol | 99% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.823 ml | 9.117 ml | 18.233 ml |
5 mM | 0.365 ml | 1.823 ml | 3.647 ml |
10 mM | 0.182 ml | 0.912 ml | 1.823 ml |
50 mM | 0.036 ml | 0.182 ml | 0.365 ml |
- 提示:詳情請(qǐng)下載說(shuō)明書(shū)。
- 產(chǎn)品描述: AMI-1 is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding
- 靶點(diǎn): IC50: 8.8 μM (PRMT1), 3.0 μM (yeast-Hmt1p);HistoneMethyltransferase
- 體內(nèi)研究:
AMI-1 (0.5 mg; intratumorally; daily; for 7 days) inhibits S180 viability in vivo. AMI-1 (0.5 mg; intratumorally; daily; for 7 days) downregulates PRMT5 but does not regulate the expression of PRMT7 in a tumor xenograft model. AMI-1 (0.5 mg; intratumorally; daily; for 7 days) decreases the levels of H4R3me2s and H3R8me2s in a tumor xenograft model
- 參考文獻(xiàn):
1. Zhang, B., et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015 Sep 8;6(26):22799-811. 2. Baolai Zhang, et al. Arginine Methyltransferase inhibitor-1 Inhibits Sarcoma Viability in vitro and in vivo. Oncol Lett. 2018 Aug;16(2):2161-2166. 3. Donghang Cheng, et al. Small Molecule Regulators of Protein Arginine Methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9.
- 溶解性: H2O : 62.5 mg/mL (113.96 mM; ultrasonic and warming and heat to 60°C)
- 保存條件: 2-8℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 1.823 ml 9.117 ml 18.233 ml 5 mM 0.365 ml 1.823 ml 3.647 ml 10 mM 0.182 ml 0.912 ml 1.823 ml 50 mM 0.036 ml 0.182 ml 0.365 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)